| Document |
Document Title |
|
JP5809367B2 |
Provided are a new crystalline form of levonorgestrel, which is useful as an emergency contraception, etc., a manufacturing method for the same, and a drug composition. The powder X-ray diffraction spectrum of this β crystalline polym...
|
|
JP2015147774A |
To provide: steroid compounds with increased resistance against metabolism and increased water solubility which act on the γ-aminobutyric acid receptor-chloride ionophore (GABA-R) complex and are used in the treatment of disorders of th...
|
|
JP5727370B2 |
A method of inhibiting growth of cancer cells comprising contacting cancer cells with a 6-substituted estradiol derivative in an amount at least partially sufficient to inhibit said growth is disclosed. The compounds have the general for...
|
|
JP5717312B2 |
Compositions and methods for alleviating the symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome are provided. The compositions are based on use of a transdermal gel formulation delivery system for androgens, eith...
|
|
JP2015511587A |
The present invention relates to four types of crystalline compounds of androstane-3β, 5α, 6β-triol (abbreviated as YC-6) (that is, A crystalline YC-6, B crystalline YC-6, C crystalline YC). -6, D crystalline form YC-6) and methods fo...
|
|
JP5642126B2 |
To provide a material for forming a self-organization pattern that can make a nanometer order fine pattern in which etching resistance is high.Provided is a compound in which a silsesquioxane skeleton having a group selected from a group...
|
|
JP2014231526A |
To provide methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds.The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,...
|
|
JP2014523903A |
this indication -- composition of aryl fluoride -- for example18It is related with a reagent and a method useful to the manufacture of a radioactive tracer in which the sign was carried out by F. The reagent and method of indicating in t...
|
|
JP5583882B2 |
The present invention relates to compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The compositions are useful for treating diseases sub...
|
|
JP5579058B2 |
Compound of formula (I), wherein the symbol have the meaning reported in the text; for preparing a medicament for the prevention and/or treatment of obstructive vascular lesions following vascular surgery and for the prevention and/or tr...
|
|
JP2014515025A |
The present invention can be used as an antitumour drug for testosterone-dependent tumours, in particular prostate cancer. The invention relates to a molecular compound composed of testosterone molecules chemically bonded to a chemothera...
|
|
JP2014094952A |
To provide a method for administering androgen excessively to skin and treating acne, baldness or hirsutism of subjects or patients as the result.Anti-androgen compounds for example having following chemical structures are administered. ...
|
|
JP2014508784A |
The present application discloses 17β hydroxy steroid dehydrogenase (17β HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17β HSD1 inhibitors include estradiol ...
|
|
JP5456669B2 |
The present invention relates to antiandrogenic compounds which may be administered for the treatment of androgen excess in the skin and by way of consequence, the treatment of acne, baldness or hirsuitism in subject or patient. These co...
|
|
JP5438503B2 |
Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are ...
|
|
JP2014505721A |
The present invention provides an improved process for preparation of levonorgestrel (3) which comprises of hydrolysis of 13beta-ethyl-3-methoxy-17alpha-ethynyl-gona-2,5(10)-dien-17b
eta-ol (2) with an acid in aprotic solvent. The presen...
|
|
JP5436432B2 |
New aminooxime derivatives at position 3 of 2- and/or 4-substituted androstanes and androstenes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as h...
|
|
JP5413836B2 |
In various aspects, the present teachings provide labeling reagents and sets of labeling reagents for the relative quantitation, absolute quantitation, or both, of hydroxylated compounds including, but not limited to, hydroxylated ring c...
|
|
JP5324921B2 |
This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders. In one embodiment the analogs are represented by t...
|
|
JP5317381B2 |
2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is particularly suitable for clinical use in humans. The purificatio...
|
|
JP2013537219A |
Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus erythematosus. Also provided are methods of producing the inclusio...
|
|
JP5290189B2 |
A compound having the structure : wherein R1, R2, R3, R4, R5, R6, R7 and R9 are independently hydrogen, C1 to C6 alkyl or substituted alkyl, halogen, sulfate or glucuronide moieties; the ---- symbol represents either a single or a double...
|
|
JP5282084B2 |
A process of making an aromatase inhibitor of formula (I) wherein each of R1, R2, R3, and R4, independently, is hydrogen, halogen, or C1-C6 alkyl, comprising reacting a compound of formula (II) with an acid in the presence of a suitable ...
|
|
JP5268635B2 |
The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17ß-hydroxysteroid dehydrogenase type I (17ß-HSD1) and, in addition, which may represent inhibitors of the steroid sulpha...
|
|
JP5264760B2 |
This invention relates to novel substituted estratrien derivatives of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder requiring the inhibition of a 17ß...
|
|
JP5255444B2 |
6-Methyloxaalkyl exemestane compounds and related compositions, as can be used, chemotherapeutically, to inhibit growth and proliferation of cancer cells.
|
|
JP5250174B2 |
The invention relates to a process for the preparation of 7α-methyl hydroxy steroids of the formula I wherein R1 is hydrogen, methyl or C≡CH; R2 is (CH2)nOH, wherein n is 0, 1 or 2; by a copper mediated 1,6-conjugate addition of a Gri...
|
|
JP5243264B2 |
A process for the recovery and purification of natural hydrophilic water-soluble products in conjugated form from vegetable aqueous extracts or physiological fluids, by adsorption of the extracts or fluids on a lipophilic resin, followed...
|
|
JP5232083B2 |
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...
|
|
JP5230449B2 |
The present invention is directed to novel 11-phosphorous steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.
|
|
JP5230450B2 |
The present invention is directed to novel 17-phosphorous steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.
|
|
JP5227593B2 |
Disclosed are compounds of the formula (I) wherein R is C1-C30 alkyl, which may be optionally further substituted with one or more of C5-C8 cycloalkyl groups, or a C5-C12 cycloalkyl, which may be optionally substituted with one or more C...
|
|
JPWO2011108661A1 |
The present invention provides a method for producing a silyl enol ether compound which is simple, versatile, and has a low environmental load (less waste). The present invention is characterized in that a ketone or aldehyde compound (1)...
|
|
JP5180125B2 |
This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for amelirating psychotic major depression. Mifepristone, a potent glucocorticoid receptor antagonist, can...
|
|
JP5113832B2 |
A process for the enantioselective reduction of compounds having a steroid structure (ABCD) including one or several heteroatoms, one or several double bonds and/or aromatic components in the ring structure and having at least one oxo gr...
|
|
JP5075626B2 |
The invention provides a process for the preparation of 2-substituted-derivatives of estrone and estradiol comprising i) the preparation of a compound of general formula (II) by reacting a compound of general formula (I) in one or more s...
|
|
JP5075629B2 |
Process for the preparation of a compound of general formula (II) wherein R1 and R2 independently are hydrogen or a hydroxy- or hydrocarbyl group; or wherein R1 and R2 together are a double bonded oxygen; R3 is hydrogen; R′4 is a nitro...
|
|
JP2012211132A |
To provide a 2-methoxyestradiol free of foreign substances.The 2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is pa...
|
|
JP5042411B2 |
There is provided use of a cyclic compound or a pharmaceutically active salt thereof in the manufacture of a medicament to prevent and/or inhibit and/or arrest cell cycling, wherein the cyclic compound comprises at least one ring, wherei...
|
|
JP5027373B2 |
|
|
JP5000294B2 |
There is provided a compound of Formula I wherein (I) R 1 is a selected from (i) an alkyloxyalkyl group (ii) a nitrile group, and wherein R 2 is capable of forming a hydrogen bond (iii) alkylaryl group, wherein the aryl group is substitu...
|
|
JP4981683B2 |
The present invention relates to a method for preparation of organofluoro compounds containing radioactive isotope fluorine-18. More particularly, the present invention relates to a method for preparation of primary or secondary organofl...
|
|
JP4977124B2 |
The invention discloses the demethylation of 5-methoxyflavonoids by bacterial enzymes, the use of these enzymes in the production of phytoestrogens in vitro, and in pharmaceutical compositions in combination with a source of methylated 5...
|
|
JP4971179B2 |
The invention relates to an industrial process for the preparation of 17-hydroxy-6β,7β;15β,16β-bismethylene-3-oxo-17α-pregn-4
-ene-21-carboxylic acid γ-lactone of formula (I), and to the key-intermediates for this process.
|
|
JP4959063B2 |
|
|
JP2012512818A |
The present invention relates to the use of estriol in the preparation of a pharmaceutical formulation for vaginal administration with the capacity to self-limit the absorption of estriol, for the prevention and/or the treatment of uroge...
|
|
JP4942905B2 |
3-Hydroxy-7β-hydroxy steroids and 3-oxo-7β-hydroxy steroids and pharmaceutically acceptable esters thereof are useful for protection against neuronal damage.
|
|
JP4926071B2 |
The present invention relates to a process for production of a steroid compound having a partial structure represented by Formula (2) by oxidizing a steroid compound having a partial structure represented by Formula (1), without the need...
|
|
JP2012509351A |
Methods for fluorinating organic compounds are described herein.
|
|
JP4920822B2 |
The use of estrogen formation inhibitor(s) (I) is claimed for the preparation of a topical medicament for the prophylaxis and/or treatment of breast cancer.
|
